Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Survey by National Business Group on Health also finds growing momentum behind use of copay accumulator programs.
CEO Merlo downplays importance of rebates to the firm’s financials as he rebuts accusations that PBMs cause high list prices for drugs.
Biosimilars for Remicade and Neulasta could get boost, and off-label Avastin use for age-related macular degeneration could increase, challenging Eylea and Lucentis.
Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.